Posters

Mid-term assessment of findings following implantation of a trabecular micro-bypass stent and cataract surgery via phacoemsulfication in patients with mild–moderate open-angle glaucoma and cataract

Poster Details

First Author: M. Kozera POLAND

Co Author(s):    J. Jablonska   K. Lewczuk   M. Rekas              

Abstract Details

Purpose:

The objective is to evaluate mid-term safety and efficacy parameters following minimally-invasive ab interno surgery using a trabecular bypass implant during cataract surgery in patients with mild and moderate open-angle glaucoma and cataract.

Setting:

Department of Ophthalmology Military Institute of Medicine, Warsaw

Methods:

This prospective, uncontrolled, interventional case series included 54 patients with a mean age of 72 years at the time of surgery. All subjects underwent ab interno implantation of a single iStent in conjunction with cataract surgery. Preoperative and postoperative parameters included corrected distance visual acuity (CDVA), IOP, topical ocular hypotensive medications, visual field, and the number and type of complications. Following surgery, patients were assessed at 1, 7 and 30 days and 3, 6, 12, 24 and 36 months.

Results:

The mean observation time was 20 months. Preoperative CDVA was 0.5 or better in 65% of eyes, and improved to 0.5 or better in all eyes (0.8 or better in 79%) at patients’ last reported exam. The mean preoperative IOP was 17.1 mmHg and reduced to a mean of 15.1 mmHg. The mean number of hypotensive eyedrops prescribed preoperatively was 1.7; this decreased to a mean of 0.26 at the end of the observation.

Conclusions:

In patients with mild to moderate open-angle glaucoma and cataract, combined cataract surgery with implantation of iStent seems to be an effective procedure. The use of 1 stent resulted in a significant decrease in intraocular pressure as well as reduction in the number of topical ocular hypotensive medications. Based on the profile of observed complications, iStent implantation can be considered a safe treatment option for these patients.

Financial Disclosure:

NONE